Literature DB >> 34724586

EUS-guided biliary drainage with LAMS for distal malignant biliary obstruction when ERCP fails: single-center retrospective study and maldeployment management.

Roberto Di Mitri1, Michele Amata2, Filippo Mocciaro1, Elisabetta Conte1, Ambra Bonaccorso1, Barbara Scrivo1, Daniela Scimeca1.   

Abstract

BACKGROUND: EUS-guided biliary drainage (EUS-BD) with Lumen Apposing Metal Stent (LAMS) is a mini-invasive approach for jaundice palliation in distal malignant biliary obstruction (D-MBO) not amenable to ERCP, with good efficacy and not exiguous adverse events. AIMS AND METHODS: From January 2015 to December 2019, we retrospectively enrolled all the EUS-BD with electrocautery-enhanced LAMS for biliary decompression in unresectable D-MBO and failed ERCP. Primary study aims were to evaluate technical/clinical success and AEs rate. In case of maldeployment, we estimated the efficacy of an intra-operative rescue therapy. Secondary aims were to assess the jaundice recurrence and gastric outlet obstruction symptoms.
RESULTS: Thirty-six EUS-BD were enrolled over a cohort of 738 patients (ERCP cannulation failure rate was 2.6%): 31 choledocho-duodenostomy and 5 cholecystogastrostomy. A pre-loaded guidewire through the LAMS was systematically used in case of common bile duct ≤ 15 mm or scope instability for a safe/preventive biliary entryway in case of intra-procedural complications. Technical success was 80.6% (29/36 patients). Seven cases of LAMS maldeployment during EUS-guided choledocho-duodenostomy were successfully treated with RT by an over-the-wire fully-covered Self-Expandable Metal Stent (FC-SEMS). The FC-SEMS was released through the novel fistula tract in endoscopic fashion in 5/7 cases and transpapillary in percutaneous-transhepatic-endoscopic rendezvous (1/7) and laparoscopic-endoscopic rendezvous (1/7) in the two remaining cases. The total efficacy of rescue therapy was 100%. Same-session duodenal SEMS was placed in 17 patients with optimal gastric outlet obstruction management. Final clinical success was 100% and no other late adverse events or FC-SEMS migration were observed.
CONCLUSION: EUS-BD with LAMS is effective for jaundice palliation after ERCP failure but with considerable adverse events. Maldeployment remains a serious complication with fatal evolution if not correctly recognized/managed. Rescue therapy must be promptly applied especially in tertiary-care centers with highly skilled endoscopists, interventional radiologist and dedicated surgeon.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Distal malignant biliary obstruction (D-MBO); ERCP; EUS-guided biliary drainage; Lumen apposing metal stent (LAMS); Maldeployment

Mesh:

Year:  2021        PMID: 34724586     DOI: 10.1007/s00464-021-08808-0

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   3.453


  49 in total

1.  Palliation of obstructing gastric cancer with steel mesh, self-expanding endoprostheses.

Authors:  M Topazian; E Ring; J Grendell
Journal:  Gastrointest Endosc       Date:  1992 Jan-Feb       Impact factor: 9.427

2.  ASGE guideline: the role of ERCP in diseases of the biliary tract and the pancreas.

Authors:  Douglas G Adler; Todd H Baron; Raquel E Davila; James Egan; William K Hirota; Jonathan A Leighton; Waqar Qureshi; Elizabeth Rajan; Marc J Zuckerman; Robert Fanelli; Jo Wheeler-Harbaugh; Douglas O Faigel
Journal:  Gastrointest Endosc       Date:  2005-07       Impact factor: 9.427

3.  Endoscopic ultrasound guided biliary drainage.

Authors:  Ilaria Tarantino; Luca Barresi; Carlo Fabbri; Mario Traina
Journal:  World J Gastrointest Endosc       Date:  2012-07-16

Review 4.  Combined percutaneous and endoscopic procedures for bile duct obstruction.

Authors:  D F Martin
Journal:  Gut       Date:  1994-08       Impact factor: 23.059

5.  Surgical palliation for unresected cancer of the exocrine pancreas.

Authors:  M Huguier; H Baumel; J C Manderscheid; S Houry; J M Fabre
Journal:  Eur J Surg Oncol       Date:  1993-08       Impact factor: 4.424

6.  Long-term outcome of palliative therapy for gastric outlet obstruction caused by unresectable gastric cancer in patients with good performance status: endoscopic stenting versus surgery.

Authors:  Jin Hee No; Sang Woo Kim; Chul-Hyun Lim; Jin Su Kim; Yu Kyung Cho; Jae Myung Park; In Seok Lee; Myung-Gyu Choi; Kyu Yong Choi
Journal:  Gastrointest Endosc       Date:  2013-03-20       Impact factor: 9.427

7.  Comparison of duodenal stent placement with surgical gastrojejunostomy for palliation in patients with duodenal obstructions caused by pancreaticobiliary malignancies.

Authors:  I Maetani; T Tada; T Ukita; H Inoue; Y Sakai; J Nagao
Journal:  Endoscopy       Date:  2004-01       Impact factor: 10.093

8.  Impact of carcinomatosis and ascites status on long-term outcomes of palliative treatment for patients with gastric outlet obstruction caused by unresectable gastric cancer: stent placement versus palliative gastrojejunostomy.

Authors:  Chan Hyuk Park; Jun Chul Park; Eun Hye Kim; Hyunsoo Chung; Ji Yeong An; Hyoung-Il Kim; Sung Kwan Shin; Sang Kil Lee; Jae-Ho Cheong; Woo Jin Hyung; Yong Chan Lee; Sung Hoon Noh; Choong Bae Kim
Journal:  Gastrointest Endosc       Date:  2014-07-30       Impact factor: 9.427

9.  Palliative gastrojejunostomy versus endoscopic stent placement for gastric outlet obstruction in patients with unresectable gastric cancer: a propensity score-matched analysis.

Authors:  Seung Hyeon Jang; Hyuk Lee; Byung-Hoon Min; Su Mi Kim; Hye Seung Kim; Keumhee C Carriere; Yang Won Min; Jun Haeng Lee; Jae J Kim
Journal:  Surg Endosc       Date:  2017-03-09       Impact factor: 4.584

10.  Stenting versus gastrojejunostomy for management of malignant gastric outlet obstruction: comparison of clinical outcomes and costs.

Authors:  Ann Roy; Micheline Kim; John Christein; Shyam Varadarajulu
Journal:  Surg Endosc       Date:  2012-05-02       Impact factor: 4.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.